ChiCTR2600118030 版本V1.0 版本创建时间2026/01/31 15:21:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118030 

最近更新日期:

Date of Last Refreshed on:

2026-01-31 15:21:20 

注册时间:

Date of Registration:

2026-01-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

乳腺癌患者化疗相关味觉改变的轨迹及其对营养状况的影响:一项前瞻性纵向研究

Public title:

The trajectory of chemotherapy-related taste changes in breast cancer patients and its impact on nutritional status : A prospective longitudinal study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳腺癌患者化疗相关味觉改变的轨迹及其对营养状况的影响:一项前瞻性纵向研究

Scientific title:

The trajectory of chemotherapy-related taste changes in breast cancer patients and its impact on nutritional status : A prospective longitudinal study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐佳圆 

研究负责人:

徐佳圆 

Applicant:

xujiayuan 

Study leader:

Xujiayuan 

申请注册联系人电话:

Applicant telephone:

+86 19858117910

研究负责人电话:

Study leader's telephone:

+86 86 86008650

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

19858117910@163.com

研究负责人电子邮件:

Study leader's E-mail:

19858117910@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市钱塘区九号大街9号

研究负责人通讯地址:

浙江省杭州市钱塘区九号大街9号

Applicant address:

No.9, No.9 Avenue, Qiantang District, Hangzhou City, Zhejiang Province, China

Study leader's address:

No.9, No.9 Avenue, Qiantang District, Hangzhou City, Zhejiang Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江中医药大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Zhejiang Chinese Medical University

研究负责人所在单位:

浙江中医药大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Zhejiang Chinese Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KLS-938-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江中医药大学附属第一医院伦理委员会

Name of the ethic committee:

EC/IRB of the First Affiliated Hospital of Zhejiang Chinese Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-07 00:00:00

伦理委员会联系人:

夏冰

Contact Name of the ethic committee:

Xia Bing

伦理委员会联系地址:

浙江省杭州市钱塘区九号大街9号

Contact Address of the ethic committee:

No.9, No.9 Avenue, Qiantang District, Hangzhou City, Zhejiang Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 86620373

伦理委员会联系人邮箱:

Contact email of the ethic committee:

allan.xia.1989@163.com

研究实施负责(组长)单位:

浙江中医药大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Zhejiang Chinese Medical University

研究实施负责(组长)单位地址:

浙江省杭州市钱塘区九号大街9号

Primary sponsor's address:

No.9, No.9 Avenue, Qiantang District, Hangzhou City, Zhejiang Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省中医院

具体地址:

浙江省杭州市钱塘区九号大街9号

Institution
hospital:

Zhejiang Provincial Hospital of TCM

Address:

No.9, No.9 Avenue, Qiantang District, Hangzhou City, Zhejiang Province, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

optional research topic

Target disease:

breast cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

短期目标:1.明确乳腺癌患者第一周期化疗相关味觉改变的变化轨迹;2.探索影响化疗第一周期味觉改变严重程度和持续时间的影响因素。 长期目标:1.明确乳腺癌患者全周期化疗相关味觉改变的变化轨迹;2.探索影响化疗全周期味觉改变严重程度和持续时间的影响因素;3.分析不同味觉改变轨迹对患者营养状况的长期影响。  

Objectives of Study:

Short-term objectives: 1. to clarify the trajectory of taste changes associated with the first cycle of chemotherapy in breast cancer patients; 2. to explore the factors affecting the severity and duration of taste changes in the first cycle of chemotherapy. Long-term objectives: 1. to clarify the trajectory of taste changes associated with the full cycle of chemotherapy in breast cancer patients; 2. to explore the factors affecting the severity and duration of taste changes in the full cycle of chemotherapy; 3. to analyse the long-term effects of different taste change trajectories on the nutritional status of patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合原发性乳腺癌诊断标准; 2.于本院择期行首次辅助或新辅助化疗; 3.AJCC TNM分期为I~III期; 4.知晓疾病诊断和病情; 5.年龄>=18周岁; 6.无语言沟通及认知功能障碍; 7.自愿加入研究并签署知情同意书。

Inclusion criteria

1.Meet the diagnostic criteria for primary breast cancer.
2.Scheduled to receive their first cycle of adjuvant or neoadjuvant chemotherapy in our hospital.
3.Classified as American Joint Committee on Cancer (AJCC) TNM stage I to III.
4.Aware of their disease diagnosis and condition.
5.Aged 18 years or older.
6.No impairments in language communication or cognitive function.
7.Voluntarily agree to participate in the study and provide signed informed consent.

排除标准:

1.合并其他严重疾病,如严重的心、肝、肾功能不全;
2.既往有其他恶性肿瘤病史;
3.妊娠期或哺乳期女性;
4.合并其他已知会导致味觉改变或影响营养的疾病,如严重的自身免疫性疾病、未控制的糖尿病、慢性口腔疾病等;
5.正在参加其他干预性临床研究。

Exclusion criteria:

1.Presence of other severe comorbidities, such as severe cardiac, hepatic, or renal dysfunction.
2.History of other prior malignancies.
3.Pregnant or lactating women.
4.Coexisting with other known conditions that may cause taste alterations or affect nutritional status, such as severe autoimmune diseases, uncontrolled diabetes mellitus, or chronic oral diseases.
5.Concurrent participation in another interventional clinical trial.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-01 00:00:00 To 2027-06-30 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

102

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

浙江中医药大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Zhejiang Chinese Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

营养指标

指标类型:

次要指标

Outcome:

nutritive index

Type:

Secondary indicator

测量时间点:

每个化疗周期前、完成所有化疗后1个月

测量方法:

提取血液检查中的白蛋白和血红蛋白含量

Measure time point of outcome:

Before each chemotherapy cycleand at 1 month after the completion

Measure method:

The contents of albumin and hemoglobin in blood test were extracted.

指标中文名:

体重下降百分比

指标类型:

主要指标

Outcome:

The percentage of weight loss

Type:

Primary indicator

测量时间点:

每个化疗周期前,每个化疗周期第3天和第7天

测量方法:

体重下降百分比=(基线体重-当前体重)/基线体重×100%。

Measure time point of outcome:

Before each chemotherapy cycle, on day 3, on day 7 of the cycle, and at 1 month after the completion

Measure method:

Weight loss percentage = ( baseline weight-current weight ) / baseline weight × 100 %.

指标中文名:

化疗相关味觉改变

指标类型:

主要指标

Outcome:

Chemotherapy-induced Taste Alteration

Type:

Primary indicator

测量时间点:

每个化疗周期前,每个化疗周期第3天和第7天

测量方法:

化疗相关味觉改变问卷

Measure time point of outcome:

Before each chemotherapy cycle, on day 3, on day 7 of the cycle, and at 1 month after the completion

Measure method:

Fill out the questionnaire

指标中文名:

患者主观整体评估量表

指标类型:

次要指标

Outcome:

Patient-Generated Subjective Global Assessment

Type:

Secondary indicator

测量时间点:

每个化疗周期前、完成所有化疗后1个月。

测量方法:

患者主观整体评估量表

Measure time point of outcome:

Before each chemotherapy cycleand at 1 month after the completion

Measure method:

Fill out the questionnaire

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-01-31 15:21:20